ABSTRACT
Laboratory testing is an important part of the diagnostic process. Overutilization represents a failure in this process that unnecessarily increases the cost of care. Unnecessary repeat testing is a subcategory of overutilization of laboratory tests. Overutilization not only increases costs but also reduces diagnostic certainty through the generation of false-positive results and ambiguous findings, 1 which, in turn, lead to additional overutilization. Overutilization also adds unnecessary data to the health record that can obscure relevant findings 2 and increase the risk of diagnostic errors. Overutilization also has several negative impacts on downstream care delivery, including increased risk of iatrogenic anemia, [3] [4] [5] [6] increased length of stay and unplanned 30-day readmission rate, 7 and patient discomfort. [8] [9] [10] Unnecessary repeat testing can result from a single order from a provider, an automated function in an order set, or a combination of the two. Factors contributing to ordering repetitive testing by providers include patient demographics, length of stay, case complexity, lack of price transparency, and inexperience. 11 Several successful strategies reported have reduced unnecessary repeat testing, including publishing evidence-based guidelines, computerized alerts, implementing decision support tools, modifying electronic order entry settings, and physician feedback and education. [12] [13] [14] [15] [16] [17] [18] [19] [20] While several studies have documented overutilization due to repeat testing, the factors that drive unnecessary repeat testing are unknown.
The objective of this study was to determine the prevalence of unnecessary repeat testing, identify factors associated with repeat testing, and estimate the economic burden of repeat testing in a large academic medical center.
Materials and Methods
This study was performed at the University of Utah Hospital, a 527-bed academic medical center. The study was classified exempt by the institutional review board.
Our objective was to identify economically significant sources of overutilization due to potentially unnecessary repeat testing (PURT). We used two criteria to identify potential sources of PURT. First, we generated a high-impact list that included the 50 tests with the highest volume and the 50 tests with the highest overall annual cost. The union of these two lists was designated the "high-impact" list. Second, we compiled a list of tests for which recommendations for testing intervals were available (recommendation list). Recommended testing intervals were identified from a literature search (described below). Tests were included in the study only if they appeared on the high-impact list and the recommendation list.
We queried the laboratory information system to obtain inpatient order data for the set of included tests for a 1-year period (January 1, 2016, to December 31, 2016) . For each order, we collected the patient name, the time of the order, the ordering physician, and the test result. Using these data, we calculated the intertest time (ITT) for test and categorized each test result as positive or negative based on the reference range (Supplementary Table 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). We also categorized each test order as consistent or not consistent with respect to the testing interval recommendation.
We performed a literature search to identify testing interval recommendations. We searched Google Scholar using combinations of the following terms: laboratory, utilization, inappropriate, financial impact, and interventions. We also searched Epocrates, Up-to-Date, and Medscape, as well as recommendations from the following sources: The Guideline Clearing House from the Agency for Healthcare Research and Quality, the US Preventative Services Task Force, and the NICE Guidance from the National Institute for Health and Care Excellence. Scopus was then used to perform a citation (forward) and reference (backward) on the set of references identified from the sources listed above. This procedure is known as "chaining" or "snowballing."
Cost savings were estimated using the Centers for Medicare & Medicaid Services (CMS) maximum allowable reimbursement rate (MARR). The MARR was used as a surrogate for the incremental direct cost (Supplementary Table 2 ). The potential cost savings was calculated by multiplying the MARR by the volume of PURT identified for each test.
We calculated the proportion of PURT based on the identified minimum ITT for each test. We used logistic regression to test whether PURT was associated with test positivity.
Results

Selected Tests
We identified 11 tests that met the inclusion criteria for this study: lipid panel, thyroid-stimulating hormone (TSH), hemoglobin A1c (HbA 1c ), C-reactive protein (CRP), iron, ferritin, folate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, Clostridium difficile by polymerase chain reaction (CDIFFPCR), and procalcitonin (PCT).
Consistency With Recommendations and Avoidable Costs
The combined volume for the 11 tests was 25,162, of which 4,242 (17%) were repeated tests. Of the tests repeated, we identified a total of 1,849 (44%) as PURT based on the minimum ITT listed in ❚Table 1❚. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The combined potential savings by avoiding the PURT was $37,376, with PCT testing offering the highest savings opportunity at $9,114 ❚Table 2❚.
Impact of Result Positivity on Repeat Testing
We evaluated positivity rates for all 11 target tests, analyzing distinct test groups: tests that were never repeated, tests repeated after the minimum ITT had elapsed, and tests repeated before the minimum ITT had elapsed ❚Table 3❚. There was a statistically significant association (P < .05) between PURT and positivity when we considered all tests. However, only three tests showed a statistically significant relationship when analyzed individually ❚Table 4❚.
Ordering Provider Analysis
We calculated the proportion of ordering providers who order PURT. The analysis was conducted on a subgroup of six tests (lipid panel, TSH, HgA 1c , CRP, ferritin, and 25-hydroxyvitamin D). This subgroup was selected for convenience and included tests with large order volumes and a range of ITTs. We also evaluated the distribution of all providers' contributions to the total PURT volume. For the six tests, 26% (21%-38%) of ordering providers ordered PURT ❚Table 5❚.
Discussion
We evaluated the prevalence, economic impact, and determinants of PURT for the inpatient population in an academic medical center. Overall, PURT accounted for about 7% of the testing volume of the selected tests. We found that 44% of repeated tests were PURT. We estimated that the annual cost of this PURT was $37,376/y. PURT was associated with positive test results. We found that 26% of providers ordered PURT, but most (69%) of PURT was due to relatively few (10%) providers.
PURT contributes to overutilization of laboratory tests. We found that 7% of the total testing volume was PURT. In general, most other studies have found higher levels of PURT ❚Table 6❚. On average, other studies 15, 18, 20, [36] [37] [38] [39] [40] [41] [42] [43] found PURT rates of 14% (range, 6%-31%). The relatively low rate of PURT in our study may be due to institutional differences (University of Utah has had a utilization management program in place for several years 44 ), differences in the tests examined, or perhaps publication bias (ie, more extreme findings are more likely to be published). In general, the reported rates of overutilization of laboratory testing vary greatly (5%-95%). 45 CDIFFPCR testing was most consistent with clinical recommendations at 88% (95% confidence interval, 85%-91%). This may reflect greater institutional control around the utilization of this test due to the important implications it has in the CMS measure for health careassociated infections, specifically the "C difficile laboratory-identified events (intestinal infections)" metric. These results suggest that the interventions surrounding C difficile testing have been effective.
Our findings present an estimated opportunity for inpatient cost reduction of $37,376/y if all of the identified PURTs were avoided for the evaluated tests. Although the potential savings is not large, we believe it is likely a lower bound on the potential cost savings. First, our analysis was limited to 11 tests. It is likely that additional savings could be obtained if the set of tests was expanded. In addition, the estimated cost savings are for 1 year. Assuming a discount rate of 3%, the present value of a perpetuity of $37,373 is $37,373/0.03 = $1.2 million. This amount certainly warrants an intervention.
Overutilization can also have side effects that increase costs beyond the direct cost of the test. Excessive diagnostic workups increase patient safety risks and do not improve diagnostic certainty. 2, 46 Negative clinical outcomes that can result from unnecessary testing include iatrogenic anemia, [3] [4] [5] [6] increased length of stay and unplanned readmission, 7 patient discomfort [8] [9] [10] (ie, frequent phlebotomies and sleep interruptions), and patient dissatisfaction. 47 These negative effects are contrary to the aims of US health care systems, and limiting them presents a greater value than solely that of direct cost savings. Our analysis only included the direct costs associated with testing and did not include the potential downstream effects of PURT.
We found that a relatively small percentage of providers (10%) accounted for most (69%) of the PURT. This has important implications for an intervention because it is generally easier to address the outlying order behavior associated with a small number of physicians (eg, through feedback and education) than to address low-level utilization issues that are spread widely across providers. Studies on the effectiveness of targeted physician feedback have shown mixed results, [48] [49] [50] but effectiveness can be increased when education and feedback are combined with other interventions. 12, [51] [52] [53] It is interesting that an average 74% of providers never ordered a PURT for these tests during the study period. Further research is warranted to identify factors that are associated with PURT. In particular, the evidence base for appropriate testing intervals needs to expand. PURT is an important driver of overutilization, and a greater understanding is needed. Our study has several limitations. Our study was performed at a single organization on a relatively small volume of tests. Thus, our findings may not be generalizable. We studied only one factor to explain PURT. We also limited our study to inpatients. We excluded outpatients because outpatients can move between providers, and we had concerns about the accuracy of testing frequency statistics in outpatients. Although such studies present challenges, future studies should explore repeat testing in inpatients.
In summary, our study showed that PURT contributes to unnecessary laboratory costs. We found that a small percentage of providers accounts for most of the PURT, and PURT is associated with positive test results.
